Please assess the completion status of the following clinical trial:

Trial Title: Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial Magnetic Resonance Imaging Sub-study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Eligible for, randomised and continuing in TRIDENT Main Study~2. No contraindications to MRI scan of the brain~3. Provide informed consent for the MRI Sub-Study~Exclusion Criteria:~1. Any MRI contraindications (e.g. metallic implants, claustrophobia, etc.)~2. Less than 6 weeks or greater than 6 months post-randomisation (however, where possible the baseline MRI Sub-Study scan should be conducted as soon as possible after the qualifying ICH. e.g. if the qualifying ICH was 4 months prior to randomisation, the baseline scan should be done as close to 6 weeks post-randomisation as possible)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Pill (Active Treatment) (Type: EXPERIMENTAL): telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg;
- Placebo (Type: PLACEBO_COMPARATOR): received via blinded study oral capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).